Mpox vaccine maker Bavarian Nordic seeks ‘critical’ EU approval for teens after WHO declares health emergency

Danish biotech company Bavarian Nordic said Friday that it had submitted data to the Europe Union’s drug regulator to extend the use of its mpox vaccine for teenagers.

CEO Paul Chaplin told CNBC that the expanded approval for 12 to 17 year-olds would be crucial in tackling the latest outbreak, which particularly afflicts teenagers and young children.